том 9 издание 30 номер публикации e202401216

Advancement of DDR1 and DDR2 Inhibitors: Therapeutic Potential of Bioactive Compounds, Designing Strategies, and Structure‐Activity Relationship (SAR)

Тип публикацииJournal Article
Дата публикации2024-08-06
scimago Q3
wos Q3
white level БС2
SJR0.366
CiteScore3
Impact factor2
ISSN23656549
Краткое описание

DDR1 and DDR2 are nonintegrin collagen receptors in the receptor tyrosine kinase family. Both DDRs bind to various collagen types and perform crucial functions in embryo development. DDRs are different from other receptor tyrosine kinases due to their interaction with extracellular matrix components and unusual activation kinetics. DDR regulates cell migration, survival, proliferation, differentiation, and extracellular matrix remodeling. Dysregulated DDR function is linked to the advancement of several human illnesses, including fibrosis, arthritis, neurodegenerative diseases, and cancer. DDRs play a vital role in disease progression and development. Therefore, the use of DDR inhibitors represents a promising therapeutic strategy, particularly for disorders with limited therapy alternatives. In recent years, DDRs have been regarded as attractive targets for drug development, as evidenced by a significant rise in research in this field. The current review illustrates about recent advancement of small molecules, their designing strategies and structure‐activity relationship. The DDR inhibitors can contain various core structures such as pyrimidine, phthalazine, pyrazole, pyrazine, imidazo[1,2‐ a ]sspyrazine, quinazoline, and thieno[3,2‐ b ]pyridin‐7‐yl derivatives. Furthermore, based on the constructive analysis of the published derivatives, we found that the majority of the powerful compounds have a similar scaffold (amide linker, hydrophobic tail, hinge binder with or without spacer). Among the different literature, the most potent compounds 4 ( imidazo[1,2‐ a ]pyrazine ) , 5 (pyridine), 19 (pyridine), and 24 (quinazoline) displayed potent activity against DDR1 with IC 50 values ranging from 2.26 – 4.67 nM, while DDR2 IC 50 values ranging from 3.2 – 7.29 nM. This approach will help medicinal chemists to refine and develop novel small molecules targeting DDR1 and DDR2.

Для доступа к списку цитирований публикации необходимо авторизоваться.

Топ-30

Журналы

1
2
Molecular Diversity
2 публикации, 33.33%
Bioorganic Chemistry
1 публикация, 16.67%
In Silico Pharmacology
1 публикация, 16.67%
Experimental Hematology and Oncology
1 публикация, 16.67%
Acta Histochemica et Cytochemica
1 публикация, 16.67%
1
2

Издатели

1
2
3
4
Springer Nature
4 публикации, 66.67%
Elsevier
1 публикация, 16.67%
Japan Society of Histochemistry and Cytochemistry
1 публикация, 16.67%
1
2
3
4
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
7
Поделиться
Цитировать
ГОСТ |
Цитировать
Pal R. et al. Advancement of DDR1 and DDR2 Inhibitors: Therapeutic Potential of Bioactive Compounds, Designing Strategies, and Structure‐Activity Relationship (SAR) // ChemistrySelect. 2024. Vol. 9. No. 30. e202401216
ГОСТ со всеми авторами (до 50) Скопировать
Pal R., Kumaraswamy B., Md. Ashadul S. K., Hosamani K. R., Gurubasavaraja Swamy P. M. Advancement of DDR1 and DDR2 Inhibitors: Therapeutic Potential of Bioactive Compounds, Designing Strategies, and Structure‐Activity Relationship (SAR) // ChemistrySelect. 2024. Vol. 9. No. 30. e202401216
RIS |
Цитировать
TY - JOUR
DO - 10.1002/slct.202401216
UR - https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/slct.202401216
TI - Advancement of DDR1 and DDR2 Inhibitors: Therapeutic Potential of Bioactive Compounds, Designing Strategies, and Structure‐Activity Relationship (SAR)
T2 - ChemistrySelect
AU - Pal, Rohit
AU - Kumaraswamy, B.
AU - Md. Ashadul, S. K.
AU - Hosamani, Ketan R.
AU - Gurubasavaraja Swamy, Purawarga Matada
PY - 2024
DA - 2024/08/06
PB - Wiley
IS - 30
VL - 9
SN - 2365-6549
ER -
BibTex
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2024_Pal,
author = {Rohit Pal and B. Kumaraswamy and S. K. Md. Ashadul and Ketan R. Hosamani and Purawarga Matada Gurubasavaraja Swamy},
title = {Advancement of DDR1 and DDR2 Inhibitors: Therapeutic Potential of Bioactive Compounds, Designing Strategies, and Structure‐Activity Relationship (SAR)},
journal = {ChemistrySelect},
year = {2024},
volume = {9},
publisher = {Wiley},
month = {aug},
url = {https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/slct.202401216},
number = {30},
pages = {e202401216},
doi = {10.1002/slct.202401216}
}
Ошибка в публикации?